Kelley Morgan - T2 Biosystems Chief Officer
| TTOODelisted Stock | USD 0.18 0.05 21.74% |
Insider
Kelley Morgan is Chief Officer of T2 Biosystems
| Age | 49 |
| Phone | 781 761 4646 |
| Web | https://www.t2biosystems.com |
T2 Biosystems Management Efficiency
The company has return on total asset (ROA) of (0.9046) % which means that it has lost $0.9046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.2214) %, meaning that it created substantial loss on money invested by shareholders. T2 Biosystems' management efficiency ratios could be used to measure how well T2 Biosystems manages its routine affairs as well as how well it operates its assets and liabilities.T2 Biosystems currently holds 49.5 M in liabilities with Debt to Equity (D/E) ratio of 6.64, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. T2 Biosystems has a current ratio of 1.83, which is within standard range for the sector. Debt can assist T2 Biosystems until it has trouble settling it off, either with new capital or with free cash flow. So, T2 Biosystems' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like T2 Biosystems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TTOO to invest in growth at high rates of return. When we think about T2 Biosystems' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Nick DeLong | iBio, Common Stock | N/A | |
| Randy Maddux | iBio, Common Stock | 63 | |
| Allison Ballmer | Agilent Technologies | N/A | |
| Francine MD | Senseonics Holdings | 73 | |
| Susan Rataj | Agilent Technologies | 63 | |
| Stephen Kilmer | iBio, Common Stock | N/A | |
| Katharine Knobil | Agilent Technologies | 56 | |
| Lisa Middlebrook | iBio, Common Stock | N/A | |
| Otis Brawley | Agilent Technologies | 61 | |
| Daniel MD | Tonix Pharmaceuticals Holding | N/A | |
| Thomas III | iBio, Common Stock | 57 | |
| Mike Jenkins | iBio, Common Stock | N/A | |
| Padraig McDonnell | Agilent Technologies | 53 | |
| Dr DVM | iBio, Common Stock | 55 | |
| Darlene Solomon | Agilent Technologies | 65 | |
| Mikael Dolsten | Agilent Technologies | 62 | |
| Robert Lutz | iBio, Common Stock | 55 | |
| Melissa Berquist | iBio, Common Stock | N/A | |
| CPA CPA | Tonix Pharmaceuticals Holding | 50 | |
| Seth MD | Tonix Pharmaceuticals Holding | 67 | |
Management Performance
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 |
T2 Biosystems Leadership Team
Elected by the shareholders, the T2 Biosystems' board of directors comprises two types of representatives: T2 Biosystems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TTOO. The board's role is to monitor T2 Biosystems' management team and ensure that shareholders' interests are well served. T2 Biosystems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, T2 Biosystems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Smith, Senior Development | ||
| Aparna MD, Chief Board | ||
| Kelley Morgan, Chief Officer | ||
| BSc III, CEO President | ||
| Michael Esq, Sr Counsel | ||
| Brett Giffin, Chief Officer | ||
| Alec Barclay, Senior Vice President - Operations | ||
| John CPA, Chief Officer |
TTOO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is T2 Biosystems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 21.91 M | ||||
| Shares Outstanding | 21.04 M | ||||
| Shares Owned By Insiders | 10.17 % | ||||
| Shares Owned By Institutions | 73.51 % | ||||
| Number Of Shares Shorted | 826.91 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in TTOO Pink Sheet
If you are still planning to invest in T2 Biosystems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the T2 Biosystems' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |